|
gptkbp:instanceOf
|
gptkb:drug
antiarrhythmic agent
|
|
gptkbp:approvedBy
|
1962
|
|
gptkbp:ATCCode
|
C01BD01
|
|
gptkbp:bioavailability
|
30-80%
|
|
gptkbp:brand
|
Cordarone
Pacerone
|
|
gptkbp:CASNumber
|
1951-25-3
|
|
gptkbp:chemicalFormula
|
C25H29I2NO3
|
|
gptkbp:contraindication
|
gptkb:second-_or_third-degree_AV_block
bradycardia
severe sinus-node dysfunction
|
|
gptkbp:discoveredBy
|
Labaz
|
|
gptkbp:eliminationHalfLife
|
20-100 days
|
|
gptkbp:excretion
|
biliary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amiodarone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
beta blocker
sodium channel blocker
potassium channel blocker
beta-adrenergic blocker
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
645.32 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
pulmonary fibrosis
photosensitivity
liver toxicity
thyroid dysfunction
corneal microdeposits
|
|
gptkbp:usedFor
|
gptkb:atrial_fibrillation
gptkb:supraventricular_tachycardia
gptkb:ventricular_fibrillation
gptkb:ventricular_tachycardia
|
|
gptkbp:bfsParent
|
gptkb:Atrial_Flutter
|
|
gptkbp:bfsLayer
|
7
|